Wcn26-5558 Efficacy and Safety of Hsk39297, a Once-Daily Oral CFB Inhibitor, in Patients With Primary Immunoglobulin a Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial

Jicheng Lv; Jiang Liu; Huaying Pei; Yan Hao; Yanlin Li; Rui Yan; Hui Xu; Xuanyi Du; B Liu; Heng Guo; Yaling Bai; Feng Huang; Fangqiong Li; Hong Zhang

doi:10.1016/j.ekir.2026.104480

March 25, 2026Kidney International ReportsOpen Access

Wcn26-5558 Efficacy and Safety of Hsk39297, a Once-Daily Oral CFB Inhibitor, in Patients With Primary Immunoglobulin a Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy and safety of HSK39297, a CFB inhibitor, in patients with primary immunoglobulin A nephropathy.
Conducted a randomized, double-blind, placebo-controlled trial
Compared the effects of HSK39297 versus a placebo
Monitored metabolic changes and kidney function in participants
Significant metabolic alterations were observed with long-term low-dose phosphorus loading
Reduced lifespan noted without hyperphosphatemia
Sex-specific differences in outcomes were identified, likely influenced by sex hormones

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial evaluates the efficacy of a novel oral CFB inhibitor in primary immunoglobulin A nephropathy, suggesting potential therapeutic benefits.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lv et al. (2026) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e08ec https://doi.org/10.1016/j.ekir.2026.104480

View Full Paper

Ask AI

Bookmark

Share

Wcn26-5558 Efficacy and Safety of Hsk39297, a Once-Daily Oral CFB Inhibitor, in Patients With Primary Immunoglobulin a Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Wcn26-5558 Efficacy and Safety of Hsk39297, a Once-Daily Oral CFB Inhibitor, in Patients With Primary Immunoglobulin a Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading